Back to Journals » Therapeutics and Clinical Risk Management » Volume 5

Monitored anesthesia care (MAC) sedation: clinical utility of fospropofol

Authors Harris E, Lubarsky D, Candiotti KA

Published 8 December 2009 Volume 2009:5 Pages 949—959

DOI https://doi.org/10.2147/TCRM.S5583

Review by Single-blind

Peer reviewer comments 2

Eric A Harris, David A Lubarsky, Keith A Candiotti

Department of Anesthesiology, Perioperative Management, and Pain Medicine, University of Miami/Miller School of Medicine

Abstract: Fospropofol, a phosphorylated prodrug version of the popular induction agent propofol, is hydrolyzed in vivo to release active propofol, formaldehyde, and phosphate. Pharmacodynamic studies show fospropofol provides clinically useful sedation and EEG/bispectral index suppression while causing significantly less respiratory depression than propofol. Pain at the injection site, a common complaint with propofol, was not reported with fospropofol; the major patient complaint was transitory perianal itching during the drug’s administration. Although many clinicians believe fospropofol can safely be given by a registered nurse, the FDA mandated that fospropofol, like propofol, must be used only in the presence of a trained anesthesia provider.

Keywords: fospropofol, propofol, monitored anesthesia care

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]